US 12569698 B1Patent grantUnited States

Magnetic Hyperthermia for Cancer-Cell Research

Official patent title

Magnetic hyperthermia therapy for cancer treatment

Arabic title: العلاج بفرط الحرارة المغناطيسي لعلاج السرطان

Invention

Problem

Magnetic hyperthermia research needs nanoparticles that can be delivered to cancer cells and generate controlled local heat under an alternating magnetic field.

Why it matters

Localized heating may complement cancer-research strategies, but clinical relevance depends on selective delivery, field safety, thermal dosimetry, biodistribution, clearance, and evidence beyond cell culture.

Approach

The method produces Nigella sativa melanin-coated magnetite nanoparticles, contacts them with MDAMB231 or KAIMRC1 breast-cancer cells, and applies an alternating magnetic field to generate hyperthermic heat.

Who may benefit

Potential beneficiaries include magnetic-hyperthermia researchers, oncology laboratories, nanomedicine developers, biomaterials groups, and preclinical therapeutic-device teams.

Potential value

The platform combines a plant-derived melanin coating with soft-magnetic magnetite particles and defines field, magnetic-property, particle-size, and cell-contact conditions for in-vitro hyperthermia studies.

Background

Magnetic hyperthermia uses alternating fields to make magnetic particles dissipate heat near a biological target. Particle size, coating, aggregation, magnetization, coercivity, field frequency, and concentration influence heating and biological response. A melanin coating may change dispersion and surface interactions, while magnetite supplies magnetic loss. Cell-line inhibition is an early preclinical result and cannot establish therapeutic safety or efficacy in animals or people. Translation requires tumor targeting, normal-cell controls, field-dose limits, pharmacokinetics, immune response, clearance, and reproducible manufacturing.

Technology overview

The issued claims cover melanin-coated magnetite nanoparticles contacting MDAMB231 or KAIMRC1 breast-cancer cell lines and inhibiting proliferation relative to an untreated control. Claimed properties include particle diameter of 20 nm or less, coercivity of 4.5–6.5 Oe, remanence of 0.05–1 emu/g, saturation magnetization of 6.5–9 emu/g, and field frequency of 300–700 kHz. Further claims state heating the cancer to at least 45 °C within 10 minutes or at least 55 °C within 5 minutes. This is in-vitro, not clinical, evidence.

Potential applications

In-vitro breast-cancer hyperthermia research.
Magnetic nanoparticle heating studies.
Melanin-coated magnetite development.
Alternating-field dosimetry experiments.

Evidence-supported advantages

Uses a Nigella sativa-derived melanin coating.
Defines low-remanence magnetic-property ranges.
Specifies alternating-field frequency limits.
Includes two breast-cancer cell lines.
Combines nanoparticle preparation and heating steps.

Development stage

Nanoparticle characterization, magnetic heating, and breast-cancer cell-line testing are described; no animal or clinical validation was established. The development stage was not independently verified.

Commercial opportunity

The platform may support preclinical magnetic-hyperthermia research tools or nanoparticle-device co-development. Any therapeutic commercialization requires animal efficacy and toxicology, selective tumor delivery, biodistribution and clearance, normal-tissue heating controls, field and coil safety, sterile scalable manufacture, stability, quality specifications, and full medical-device and drug regulatory pathways. No clinical benefit is established.

Patent classifications

WIPO IPC

A61N2/00Electrotherapy; magnetotherapy; radiation therapy; ultrasound therapy

CPC

A61N2/004Electrotherapy; magnetotherapy; radiation therapy; ultrasound therapy

Inventors

First inventorNawal Ahmed Madkhali
InventorSaja Mohammed Algessair
InventorMarwan Mohammed Abduljawad
InventorRizwan Ali
InventorO. Mohamed Lemine

Keywords

magnetic hyperthermia
magnetite nanoparticles
Nigella sativa melanin
breast cancer cell line
alternating magnetic field
coercivity
remanence
in vitro

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.